全文获取类型
收费全文 | 55616篇 |
免费 | 3471篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 529篇 |
儿科学 | 2296篇 |
妇产科学 | 1514篇 |
基础医学 | 6949篇 |
口腔科学 | 540篇 |
临床医学 | 8544篇 |
内科学 | 9547篇 |
皮肤病学 | 759篇 |
神经病学 | 5329篇 |
特种医学 | 974篇 |
外科学 | 4603篇 |
综合类 | 590篇 |
一般理论 | 109篇 |
预防医学 | 7764篇 |
眼科学 | 760篇 |
药学 | 3636篇 |
中国医学 | 61篇 |
肿瘤学 | 4693篇 |
出版年
2023年 | 290篇 |
2022年 | 431篇 |
2021年 | 1016篇 |
2020年 | 693篇 |
2019年 | 1050篇 |
2018年 | 1202篇 |
2017年 | 977篇 |
2016年 | 1058篇 |
2015年 | 1238篇 |
2014年 | 1711篇 |
2013年 | 2728篇 |
2012年 | 3931篇 |
2011年 | 4243篇 |
2010年 | 2357篇 |
2009年 | 2128篇 |
2008年 | 3832篇 |
2007年 | 4079篇 |
2006年 | 3931篇 |
2005年 | 4070篇 |
2004年 | 3863篇 |
2003年 | 3637篇 |
2002年 | 3354篇 |
2001年 | 473篇 |
2000年 | 347篇 |
1999年 | 472篇 |
1998年 | 685篇 |
1997年 | 608篇 |
1996年 | 479篇 |
1995年 | 481篇 |
1994年 | 425篇 |
1993年 | 338篇 |
1992年 | 243篇 |
1991年 | 208篇 |
1990年 | 185篇 |
1989年 | 196篇 |
1988年 | 188篇 |
1987年 | 169篇 |
1986年 | 162篇 |
1985年 | 164篇 |
1984年 | 186篇 |
1983年 | 169篇 |
1982年 | 215篇 |
1981年 | 207篇 |
1980年 | 155篇 |
1979年 | 95篇 |
1978年 | 112篇 |
1977年 | 52篇 |
1976年 | 57篇 |
1975年 | 46篇 |
1974年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
Mats Bergstrom Azita Monazzam Pasha Razifar Susan Ide Raymond Josephsson Bengt Langstrom 《Journal of nuclear medicine》2008,49(7):1204-1210
For a PET agent to be successful as a biomarker in early clinical trials of new anticancer agents, some conditions need to be fulfilled: the selected tracer should show a response that is related to the antitumoral effects, the quantitative value of this response should be interpretable to the antitumoral action, and the timing of the PET scan should be optimized to action of the drug. These conditions are not necessarily known at the start of a drug-development program and need to be explored. We proposed a translational imaging activity in which experiments in spheroids and later in xenografts are coupled to modeling of growth inhibition and to the related changes in the kinetics of PET tracers and other biomarkers. In addition, we demonstrated how this information can be used for planning clinical trials. METHODS: The first part of this concept is illustrated in a spheroid model with BT474 breast cancer cells treated with the heat shock protein 90 (Hsp90) inhibitor NVP-AUY922. The growth-inhibitory effect after a pulse treatment with the drug was measured with digital image analysis to determine effects on volume with high accuracy. The growth-inhibitory effect was described mathematically by a combined E(max) and time course model fitted to the data. The model was then used to simulate a once-per-week treatment; in these experiments the uptake of the PET tracers (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) was determined at different doses and different time points. RESULTS: A drug exposure of 2 h followed by washout of the drug from the culture medium generated growth inhibition that was maximal at the earliest time point of 1 d and decreased exponentially with time during 10-12 d. The uptake of (18)F-FDG per viable tumor volume was minimally affected by the treatment, whereas the (18)F-FLT uptake decreased in correlation with the growth inhibition. CONCLUSION: The study suggests a prolonged action of the Hsp90 inhibitor that supports a once-per-week schedule. (18)F-FLT is a suitable tracer for the monitoring of effect, and the (18)F-FLT PET study might be performed within 3 d after dosing. 相似文献
93.
94.
95.
96.
97.
Susan Yung Heinz Hausser Gareth Thomas Liliana Schaefer Hans Kresse Malcolm Davies 《Peritoneal dialysis international》2004,24(2):147-155
OBJECTIVE: Previous studies have shown that decorin and biglycan account for over 70% of the proteoglycans (PGs) synthesized by human peritoneal mesothelial cells (HPMCs). Since these PGs are involved in the control of cell growth, cell differentiation, and matrix assembly, we investigated their turnover in cultured HPMCs. METHODS: Confluent HPMCs were metabolically labeled with [35S]-sulfate and the labeled products isolated from the cell medium and the cell layer characterized by sensitivity to bacterial eliminases. Experiments were undertaken with exogenous labeled decorin, and its metabolic state was studied. RESULTS: In a 24-hour labeling period, 75% of the newly synthesized chondroitin sulfate/dermatan sulfate (CS/DS) PGs appeared in the culture medium, the majority of which (90%) was decorin. In the cell layer, protein-free glycosaminoglycan (GAG) chains accounted for 21% of the total CS/DS at 24 hours and exhibited constant specific activity at 12-16 hours. The latter material was turned over with a half-life of approximately 2.5 hours. Exogenous decorin underwent receptor-mediated endocytosis and subsequent intracellular degradation. Uptake but not degradation could be inhibited by heparin. CONCLUSIONS: HPMCs are distinguished by a rapid turnover of decorin. A characteristic metabolic feature is the existence of a large intracellular pool of protein-free DS-GAGs. Understanding the control of decorin turnover in HPMCs might lead to delineation of its potential role in both the physiology and pathophysiology of the membrane in PD patients. 相似文献
98.
Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. 总被引:2,自引:0,他引:2
T Kuber Sampath Petra Simic Rebecca Sendak Natasa Draca Ann E Bowe Stephen O'Brien Susan C Schiavi John M McPherson Slobodan Vukicevic 《Journal of bone and mineral research》2007,22(6):849-859
We show the systemic administration of low levels of TSH increases bone volume and improves bone microarchitecture and strength in aged OVX rats. TSH's actions are mediated by its inhibitory effects on RANKL-induced osteoclast formation and bone resorption coupled with stimulatory effects on osteoblast differentiation and bone formation, suggesting TSH directly affects bone remodeling in vivo. INTRODUCTION: Thyroid-stimulating hormone (TSH) receptor haploinsufficient mice with normal circulating thyroid hormone levels have reduced bone mass, suggesting that TSH directly affects bone remodeling. We examined whether systemic TSH administration restored bone volume in aged ovariectomized (OVX) rats and influenced osteoclast formation and osteoblast differentiation in vitro. MATERIALS AND METHODS: Sprague-Dawley rats were OVX at 6 months, and TSH therapy was started immediately after surgery (prevention mode; n = 80) or 7 mo later (restoration mode; n = 152). Hind limbs and lumbar spine BMD was measured at 2- or 4-wk intervals in vivo and ex vivo on termination at 8-16 wk. Long bones were subjected to microCT, histomorphometric, and biomechanical analyses. The direct effect of TSH was examined in osteoclast and osteoblast progenitor cultures and established rat osteosarcoma-derived osteoblastic cells. Data were analyzed by ANOVA Dunnett test. RESULTS: In the prevention mode, low doses (0.1 and 0.3 microg) of native rat TSH prevented the progressive bone loss, and importantly, did not increase serum triiodothyroxine (T3) and thyroxine (T4) levels in aged OVX rats. In restoration mode, animals receiving 0.1 and 0.3 microg TSH had increased BMD (10-11%), trabecular bone volume (100-130%), trabecular number (25-40%), trabecular thickness (45-60%), cortical thickness (5-16%), mineral apposition and bone formation rate (200-300%), and enhanced mechanical strength of the femur (51-60%) compared with control OVX rats. In vitro studies suggest that TSH's action is mediated by its inhibitory effects on RANKL-induced osteoclast formation, as shown in hematopoietic stem cells cultivated from TSH-treated OVX rats. TSH also stimulates osteoblast differentiation, as shown by effects on alkaline phosphatase activity, osteocalcin expression, and mineralization rate. CONCLUSIONS: These results show for the first time that systemically administered TSH prevents bone loss and restores bone mass in aged OVX rats through both antiresorptive and anabolic effects on bone remodeling. 相似文献
99.
Cora E Lewis Susan K Ewing Brent C Taylor James M Shikany Howard A Fink Kristine E Ensrud Elizabeth Barrett-Connor Steven R Cummings Eric Orwoll 《Journal of bone and mineral research》2007,22(2):211-219
We examined determinants of nonvertebral fracture in elderly men from six U.S. communities followed an average of 4.1 years. Six clinical risk factors predicted fracture risk independent of hip BMD: tricyclic antidepressant use, previous fracture, inability to complete a narrow walk trial, falls in previous year, age > or =80 years, and depressed mood. INTRODUCTION: There are few prospective studies of fracture determinants in men. We examined the associations between a comprehensive set of clinical risk factors and risk of nonspine fracture in older men and whether determinants of fracture risk were independent of total hip BMD. MATERIALS AND METHODS: A total of 5995 men > or =65 years of age were recruited from six communities in the Unites States and followed prospectively for an average of 4.1 years. Baseline assessments of demographic, lifestyle, medical history, functional status, anthropometry, and cognitive, visual, and neuromuscular function were assessed by questionnaire or examination. Triannual mailed questionnaires ascertained incident fracture; reported fractures were adjudicated by physicians using medical records and X-ray reports. Proportional hazards models were used to develop multivariable models, selecting variables and controlling for BMD. RESULTS: Of 5876 men, 4.7% (N = 275) reported an incident nonspine fracture during follow-up (11.46/1000 person-years). Tricyclic antidepressant use (hazard ratio [HR], 2.36; 95% CI, 1.25-4.46), history of fracture at or after age 50 (HR, 2.07; 95% CI, 1.62-2.65), inability to complete a narrow walk trial (HR, 1.70; 95% CI, 1.23-2.34), falls in previous year (HR, 1.59; 95% CI, 1.23-2.05), age > or =80 years (HR, 1.33; 95% CI, 1.01-1.76), depressed mood (HR, 1.72; 95% CI, 1.00-2.95), and decreased total hip BMD (HR, 1.53; 95% CI, 1.34-1.74) were independently related to increased risk. Compared with having none (48.0% of men), having three or more of the clinical risk factors (4.9% of men) increased fracture risk 5-fold, independent of BMD. Having three or more risk factors and being in the lowest tertile of BMD was associated with a 15-fold greater risk than having no risk factors and being in the highest BMD tertile. CONCLUSIONS: Several clinical risk factors were independently associated with nonspine fractures in elderly men. The combination of multiple risk factors and low BMD was a very powerful indicator of fracture risk. 相似文献
100.